Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 1/2 study is to evaluate the efficacy and safety of treatment with
VELCADE, dexamethasone, and Revlimid® (VDR) as well as VELCADE, dexamethasone,
cyclophosphamide, and Revlimid (VDCR) in patients with multiple myeloma who have received no
prior treatment. This study will evaluate whether the addition of Revlimid to VELCADE and
Dexamethasone will increase the complete response (CR)/ very good partial response (VGPR)
rate.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.